Table 1. Inhibition of tumour development and acquisition of metastatic ability of QR-32 tumour cells by administration of oxykine (a) tumorigenicity of QR-32 cells co-implanted with gelatin sponge in mice and (b) characteristics of the arising tumour lines.
|
No. of mice with tumour take/no, of mice treated (%)
|
||||
|---|---|---|---|---|
| Treated witha | Exp. 1 | Exp. 1 | Total | No. of cell lines establihed/no of tumours tested (%)b |
| (a) Tumorigenicity of QR-32 cells co-implanted with gelatin sponge in mice | ||||
| — | — | — | — | — |
| Saline | 8/9 (89) | 7/10 (70) | 15/19 (79) | 15/19c (79) |
| Gliadin | 8/8 (100) | 7/10 (70) | 15/18 (83) | 15/18 (83) |
| Oxykine | 4/7 (57) | 6/10 (60) | 10/17 (59) | 7/17c (41) |
|
Lung-colonising ability
|
Other metastasis sites
|
|||
|---|---|---|---|---|
| Cell lines established from the arising tumour | Incidence (no. of mice with lung metastasis/no. of mice tested) | No. of lung with metastatic nodules | Incidence no. of mice with other metastases/no of mice tested) | Sites (incidence) |
| (b) Characteristics of the arising tumour lines d | ||||
| QR-32 | 0/10 | 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 | 0/10 | None |
| QRsP/-1 | 3/3 | 1, 3, 14 | 0/3 | None |
| QRsP/-2 | 3/3 | 8, 13, 20 | 0/3 | None |
| QRsP/-3 | 4/4 | 3, 8, 14, >150 | 1/4 | [O (1/4)] |
| QRsP/-4 | 3/4 | 0, 1, 3, 35 | 0/4 | None |
| QRsP/-5 | 4/5 | 0, 2, 7, 8, 15 | 1/5 | [O (1/5)] |
| QRsP/-6 | 4/4 | 8, 43, >150, >150 | 2/4 | [O (2/4)] |
| QRsP/-7 | 4/4 | 8, 11, >150, >150 | 2/4 | [O (2/4)] |
| QRsP/-8 | 4/4 | >150, >150, >150, >150 | 0/4 | None |
| QRsP/-9 | 4/4 | 16, 48, 51, 62 | 0/4 | None |
| Total | 33/35e | 6/35 | None | |
| QRsP/GD-1 | 4/4 | 2, 2, 4, 17 | 0/4 | None |
| QRsP/GD-2 | 4/4 | 5, 6, 12, 14 | 0/4 | None |
| QRsP/GD-3 | 2/4 | 0,0,3,8 | 0/4 | None |
| QRsP/GD-4 | 3/4 | 0, 5, 7, 22 | 1/4 | [O (1/4)] |
| QRsP/GD-5 | 3/4 | 0, 3, 6, 12 | 0/4 | None |
| QRsP/GD-6 | 4/4 | 2, 5, 6, 7 | 1/4 | [O (1/4)] |
| QRsP/GD-7 | 3/3 | 16, >150, >150 | 1/3 | [O (1/3), A (1/3)] |
| QRsP/GD-8 | 4/4 | 25, 58, 132, >150 | 3/4 | [O (2/4), LN(1/4] |
| QRsP/GD-9 | 4/4 | 58, 73, >150, >150 | 0/4 | None |
| QRsP/GD-10 | 4/4 | 42, 43, 123, >150 | 0/4 | None |
| Total | 35/39 | 5/39 | None | |
| QRsP/OK-1 | 0/4 | 0, 0, 0, 0 | 0/4 | None |
| QRsP/OK-2 | 3/4 | 0, 2, 3, 18 | 0/4 | None |
| QRsP/OK-3 | 2/4 | 0, 0, 5, 7 | 0/4 | None |
| QRsP/OK-4 | 0/4 | 0, 0, 0, 0 | 0/4 | None |
| QRsP/OK-5 | 1/4 | 0, 0, 0, 8 | 0/4 | None |
| QRsP/OK-6 | 0/4 | 0, 0, 0, 0 | 0/4 | None |
| QRsP/OK-7 | 1/4 | 0, 0, 0, 2 | 0/4 | None |
| Total | 7/28e | 0/28 | None | |
a
1 × 105 QR-32 tumour cells were coimplanted with gelatine sponge in normal mice to which oxykine or gliadin had been administered per os (10 mg kg−1) once daily throughout the experiment.
b
Culture cell lines were separately established from tumours arisen in each mouse.
c
P<0.05 vs saline.
d
In a separate experiment, 1 × 106 cells of each cell line were injected into mice. After 25 days, the mice were killed and metastatic nodules at the surface of lung were counted macroscopically. Incidences of lung metastasis were evaluated as follows:
e
P<0.001 vs lung-colonising incidence of saline-treated group.